Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain
Sammy Al Mukhaizeem1,2 
Anurag Nasa1,3 
Dympna Waldron4,5 Alex McDaid1,2 Patrick J. Gorman1,2 Molly Featherstone1,2 Megan Barry1,2 Paul Murphy1,2,6 
Hugh Gallagher1 Shrijit Nair1 Michael O’Connor3 
Linda Kelly3 Emma O'Hora3 Roisin Dolan7 Siaghal Mac Colgain8 Jack McGrath1 Stephane Blouin1 
Elena Roman1,3 Laura Gaffney5 Darren William Roddy3,6 
Kirk John Levins1,2,6*
- 1Department of Anaesthesia, St Vincent’s University Hospital, Dublin, Ireland
- 2School of Medicine, College of Health and Agricultural Sciences, University College Dublin, Dublin, Ireland
- 3Department of Psychiatry, Education and Research Centre, Royal College of Surgeons, Beaumont Hosptial, Dublin, Ireland
- 4Department of Palliative Medicine, Saolta Hospitals Group, Galway University Hospital, Galway, Ireland
- 5Department of Medicine, University of Galway, Galway, Ireland
- 6SPIRIT (St Vincent’s Pain Institute: Research, Innovation and Therapies), St Vincent’s University Hospital, Dublin, Ireland
- 7Department of Plastic Surgery, St Vincent’s University Hospital, Dublin, Ireland
- 8National Maternity Hospital, Dublin, Ireland
Introduction: Chronic pain is defined as pain lasting longer than 3 months. This often causes persistent emotional distress and functional disability that is refractory to conventional treatments. Emerging evidence suggests that oral Ketamine therapy may have a specific role in managing treatment-resistant chronic pain. This study aimed to assess the effectiveness of oral ketamine within a tertiary chronic pain management clinic.
Methods: This study was a clinic-based retrospective descriptive study of 79 patients with a broad range of chronic pain diagnoses and treated with oral ketamine over a period up to 12 years. Changes in pain, mood and quality of life (QoL) were assessed using a numerical pain severity score, the Brief Pain Inventory (BPI), the Public Health Questionnaire (PHQ-9) and American Chronic Pain Association Quality of Life (QoL) scale.
Results: 73 patients were accessible for follow-up (mean daily dose and treatment duration were 193.84 mg and 22.6 months respectively). Pain scores decreased (p < 0.0001) on both numerical scores (41.6% decrease) and BPI scoring (mean decrease 2.61). Mood improved (p < 0.0001) across both PHQ-9 and BPI measurements. Patients also reported less difficulty with daily activities and improved QoL. The most common adverse reaction was drowsiness (21.9%), with 30.1% reporting no adverse reactions from Ketamine.
Discussion: This work adds to the growing body of evidence that under the supervision of a pain specialist, oral ketamine therapy may be a safe, tolerable and effective treatment for chronic pain conditions which have not responded to other management options. Further research is required to produce a more accurate understanding of its chronic use.
Key message: This real-world study shows that patients being treated with oral ketamine for chronic pain report decreased severity of pain, improved mood and increased quality of life across all conditions.
Introduction
Chronic pain is pain that persists for longer than 3 months. The ICD-11 has 7 subcategories of chronic pain, categorized as primary or secondary (1). It defines primary chronic pain as pain present in at least one anatomical region that results in emotional distress or functional disability and does not fit the definition of another chronic pain condition. Fibromyalgia and complex regional pain syndrome (CRPS) are examples of these chronic pain conditions. Secondary chronic pain is defined as a symptom of an underlying condition. It can be cancer-related, post-surgical, musculoskeletal, visceral, neuropathic or orofacial (2). The prevalence of chronic pain conditions approaches 20% worldwide (3) increasing with age (4). It impacts quality of life significantly (5) and is the leading cause of years lived with disability (6). Chronic pain is also associated with decreased life expectancy (7). Living with chronic pain increases the chances of developing depression and anxiety-like symptoms as well as the diagnosis of depression and anxiety disorders (8–11). Management of chronic pain is complex and often involves a combination of interventional, pharmacological, psychological and physical therapies (12).
The N-methyl-D-aspartate receptor (NMDAR) is found on neural structures involved in nociception such as primary afferent neurons and spinal dorsal horn neurons (13). It is thought to play a role in development and persistence of chronic pain (14). These excitatory glutamatergic receptors facilitate the transmission of afferent pain signals. In chronic pain states, these receptors are upregulated in the spinal cord through long-term potentiation causing central sensitization (15). This results in patients experiencing increased pain sensitivity (hyperalgesia), pain from non-painful stimuli (allodynia) and even spontaneous pain (16). The non-competitive NMDAR antagonist ketamine has been shown to reduce allodynia and hyperalgesia in chronic pain patients and may potentially reverse the neuronal changes seen in central sensitization (17).
Ketamine (originally referred to as CI-581) was first synthesised in 1962 as a shorter-acting, and therefore safer, alternative to Phencyclidine (CI-395) (18). Both the anaesthetic and analgesic properties of ketamine are primarily due to NMDAR antagonism (19). It also acts on nicotinic, muscarinic and opioid receptors and increases ambient noradrenaline (17).
Ketamine can be administered through intravenous, intramuscular, intrarectal, oral, or intranasal routes (13). Epidural administration of ketamine is typically avoided as it enters systemic circulation. It is a lipophilic molecule with an extensive volume of distribution that undergoes extensive first pass hepatic metabolism. As such, it has a low oral bioavailability, estimated at 10%–20% (20). In adults, ketamine has an elimination half-life of 2–3 h (21) while it’s metabolite Norketamine persists 5 h after Ketamine administration (22). This causes accumulation of Norketamine which itself is implicated in the sustained analgesic effect after Ketamine has been eliminated (22).
The use of Ketamine for the treatment of chronic pain has largely been limited to those with pain resistant to other interventional options (23). There is insufficient evidence to indicate greater efficacy across administration routes of Ketamine for chronic pain. It has been shown that with IV administration, the analgesic effect of ketamine is maintained for steady-state plasma concentrations greater than 100–160 ng/ml (24). However, due to Norketamine, effective analgesic concentrations with oral Ketamine are lower at 40 ng/ml (25). Adverse effects such as psychedelic phenomena, anxiety and paranoia typically occur at higher plasma concentrations than the analgesic effect (26, 27).
This dose-dependent correlation with adverse reactions may be explained by Ketamine's action primarily on NMDA receptors at low doses, with actions on opioid, dopaminergic and monoaminergic receptors occurring at higher doses (28). Using oral formulations to achieve the lowest effective plasma concentration for analgesia seems desirable. When used for treatment resistant depression (TDD), both oral and IV ketamine have been suggested to have similar efficacy (29). The oral route of administration is a cheaper, more convenient and personally acceptable administration method for choice of maintenance treatment when compared to other routes (30).
Despite the increasing use of ketamine for chronic pain management, there remains a paucity of widespread evidence to support its effectiveness, particularly over the longer-term (31). Most studies have involved small numbers of patients, restricted diagnostic categories and short follow-up. This study aims to explore the effectiveness of oral ketamine across multiple chronic pain conditions in a retrospective study investigating pain scores, mood and quality of life (QoL) in an outpatient setting.
Methods
Study design
This was a retrospective descriptive study of 73 patients with treatment-resistant chronic pain. Ethical approval was sought prior to commencement.
Selection criteria
The criteria for this study were as follows:
• Aged >18 years
• English Fluency
• Chronic pain diagnosis of any type
• Prescribed Oral Ketamine for the treatment of chronic pain after unsatisfactory pain relief from all other available interventional options suitable to the patient
Setting
This study was conducted at the above outpatient pain clinic from June 2020 to June 2021. This is the largest tertiary-level pain clinics in Ireland. Ketamine is offered as a management option to patients with severe intractable chronic pain. It is only offered in the form of an oral solution (10 mg/ml), which patients self-administer following a training session with a specialist nurse. Ketamine is prescribed directly from this pain clinic and full prescription list was generated through a review of current and archived prescription pads.
Patients were contacted by letter with a detailed patient information leaflet (PIL) and consent form. A follow-up phone call from a member of the study team explained the PIL and consent form. Following consent, each patient was contacted to arrange a suitable time to complete the questionnaires. Both ‘pre’ and ‘post’ Ketamine responses were recorded during a single interview.
Reduce bias
To reduce bias, interviews were conducted by study team members who fulfilled the following criteria: never met the patient, never involved in the patient’s care, not licensed to prescribe ketamine in Ireland and appropriately trained in the required questionnaires.
Data collected
Interviews were performed by phone and involved applying questionnaires and scales to patients’ current situation as well as recollecting how their pain, mood and QoL were prior to starting ketamine. All data was anonymised on collection, transcribed and stored in a secure database prior to analysis. Information was elicited with:
• A standard numerical pain scale (0–10).
• Difficulty with activities of daily living (ADLs) due to pain. Difficulty was ranked as follows: 1 none, 2 mild, 3 moderate, 4 severe.
• The patient health questionnaire (PHQ-9) (32). This consists of 9 questions, screening for the common signs and symptoms of depression. The depression severity is scored as follows: 0–4 none, 5–9 mild, 10–14 moderate, 15–19 moderately severe, 20–27 severe. A PHQ-9 of ≥10 has a sensitivity and specificity of 88% for major depression.
• The brief pain inventory (BPI) (33). This questionnaire explores the impact of pain using a numerical rating (0–10) for worst, least, average, and current pain intensity and the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life. This has been shown to hold validity across cultures and languages and can be used for all types of chronic pain (34).
• American Chronic Pain Association Quality of Life Scale. This is a one-item scale measuring QoL specifically in pain populations (35). With this scale patients can succinctly describe their ability to complete ADLs measuring from 0 (no functioning) to 10 (normal daily functioning).
• A list of medications while on oral Ketamine therapy and any pain related procedures ever.
Statistical analysis
All statistical analysis of the data was performed on the IBM SPSS-27 software (https://www.ibm.com/analytics/us/en/technology/spss/). Data was pre-processed before data analysis, involving inspection and outlier winsorization of the data. The data from responses in the questionnaires were not normally distributed, so a non-parametric approach was preferred throughout the analysis. Descriptive statistics were performed. Following this, the Mann–Whitney U test was performed to compare findings between the responses for before and after initiation of Ketamine therapy.
Results
Participants
From June 2020 to June 2021, a total of 79 patients were recruited from St Vincent’s University Hospital’s Pain Management Clinic. One patient withdrew, and five others could not be reached for follow-up (Figure 1). Among the remaining 73 patients, 80.8% (n = 59) were female. The average age was 49 ± 12 years, and the average daily dose of Ketamine was 193.84 ± 176.84 mg (Table 1). The average treatment duration was 22.6 ± 26.6 months, ranging from 1 week to over 12 years, with a median of 1 year. At follow-up, 5.5% (n = 4) of patients had discontinued ketamine. For the “post” ketamine section of the questionnaire, patients were asked to recall the period immediately after completing ketamine therapy.
Figure 1. Flowchart of participant cohort. N, number.
Table 1. Sex, age and cumulative daily dose of ketamine for participants.
The patients included in this study had a range of chronic pain diagnoses (Table 2). The most common were fibromyalgia 21.9% (n = 16), peripheral neuropathy 17.8% (n = 13), chronic back/neck pain 16.4% (n = 12) and complex regional pain syndrome (CRPS) 13.7% (n = 10).
Table 2. Chronic pain diagnoses.
Interviews and questionnaires
The 10-point numerical pain scale decreased by 3.67 points following ketamine therapy. 39.7% (n = 29) reported that the nature of their pain had changed. The PHQ-9 score decreased from 15.07 to 9.97 following Ketamine treatment (Table 3).
Table 3. Scores for pain, quality of life, difficulty with activities of daily living (ADLs) and patient health questionnaire-9 (PHQ-9) before and after commencing ketamine.
BPI-scoring patients reported improvements across all 10-point domains (Table 4). Maximum, minimum and average pain were all reported to decrease (2.91, 2.16 and 2.61 respectively). The impact of pain also showed a general decrease across all BPI domains; general activity (1.23), mood (3.58), enjoyment of life (3.26), relationships (2.65), sleep (2.95), walking ability (3.58) and normal work (2.89). Patients reported experiencing less difficulty regarding activities of daily living, and QoL was found to improve by 2.43 points (Table 3).
Table 4. Brief pain inventory (BPI) scores before and after commencing ketamine.
All reported differences were significant on Mann-Whitney U testing with a significance of <0.0001, except BPI general activity, which was significant at 0.013 (Table 4).
Adverse reactions
Various adverse reactions were reported (Table 5). Drowsiness was the most reported adverse reaction at 21.92% (n = 16). Other adverse reactions include nausea 12.33% (n = 9), memory impairment 10.96% (n = 8) and dizziness 8.22% (n = 6). 30.14% (n = 22) of patients reported having no adverse reactions to Ketamine.
Table 5. Adverse reactions to ketamine.
Concurrent medications and procedures
Table 6 shows the concurrent medications used by patients while on ketamine. Opioids were the most common medication, being used by 60.3% (n = 44) of patients. Other common medications include amitriptyline 26.03% (n = 19), pregabalin 23.29% (n = 17) and gabapentin 16.44% (n = 12). 5.48% (n = 4) reported taking no concurrent medications whilst undergoing ketamine therapy.
Table 6. Concurrent medications.
Table 7 shows procedures either before or during ketamine therapy. These include nerve blocks 42.47% (n = 31), spinal cord stimulators 24.66% (n = 18), steroid injections 10.96% (n = 8) and Botox injections 9.59% (n = 7). 13.7% (n = 10) of patients reported having no previous procedures for the alleviation of pain.
Table 7. Proceudres underwent by patients for the purpose of pain relief.
Discussion
This retrospective cohort study of 73 patients with various chronic pain conditions showed decreased pain, improved mood, improved QoL and increased ease with undertaking ADLs when treated with oral ketamine.
Decreases in both the numerical pain scale and BPI pain scores were found (Tables 3, 4). Clinically signficant decreases in chronic pain have been suggested at 27.9–33% (36, 37). A 5-year retrospective study of patients with intractable chronic pain found 66% of patients reported a ≥25% reduction in baseline pain with 44% of patients reporting ≥50% reduction when treated with oral Ketamine (27). Our results of a decrease of 3.67 points (41.6%) overall in the numerical pain score and similar reductions in the BPI maximum (30.5%), minimum (37.3%) and average pain scores (35.1%) are in keeping with previous findings. 39.7% (n = 29) reported that the nature of their pain had improved since starting oral ketamine.
The PHQ-9 decreased from 15.07 to 9.97 following oral Ketamine treatment (Table 3). A change of 5 or more points on the PHQ-9 is regarded as a clinically significant improvement in mood (39) from moderately severe (score > 15) to mild/moderate depression symptoms (between 9 and 14). The PHQ-9 is a valid measure of depressive severity when used both in patients with diagnosed major depression and the general (non-diagnosed) population (32). The PHQ-9 results are reflected in the BPI mood scores with a reduction of 46.9% in depression symptoms. Ketamine has recently found traction in the treatment of resistant depression (40). Chronic pain is thought to involve similar brain changes to those found in depression (41–45), with patients up to four times more likely to suffer from depression or anxiety (46) and are twice as likely to die by suicide (2). Chronic pain patients have shown improvement in depressive symptoms using 150 mg of oral Ketamine daily (47). Whether our improvement in mood was secondary to improved pain, or through a different primary mechanism remains uncertain.
Ketamine's interaction with the dorsal diencephalic conduction system (DDCS) may help explain the improvements seen in mood. The DDCS consists of three key structures; the habenula (medial and lateral), the stria medullaris, and the fasciculus retroflexus (48). This highly conserved pathway links the monoaminergic brainstem and the basal forebrain. Most importantly, its central component modulates the lateral habenula which acts as a hub before transmitting signals to brainstem modulatory areas (49). This makes the lateral habenula imperative for the integration of emotional, cognitive, sensory and motor processing to ultimately influence value-based decision-making and motivational processing (50). It has been widely recognised, using fMRI resolutions, that the lateral habenula plays a significant role as an ‘anti-reward center’ in the mechanism of addiction and major depression (51). Ketamine has been shown to inhibit burst firing from the lateral habenula via NMDA receptor antagonism (52). This is suggested to be the primary mechanism of Ketamine's antidepressant properties.
BPI-scoring reported improvements across all domains including general activity, mood, enjoyment of life, relationships, sleep, walking ability and normal work (Table 4). Reflecting these improvement, patients reported less difficulty with activities of daily living and QoL (Table 3). A detrimental effect of living with chronic pain is clear with poorer QoL (53). Furthermore, it impacts work-related outcomes including productivity and absences (54). When self-reported pain intensity is reduced by over 50%, chronic pain sufferers consistently report improvements in work and QoL (54). Unfortunately, up to 79% of chronic pain patients report their pain as being ineffectively managed (55).
Oral ketamine has been reported to be generally well tolerated when used in treatment of both chronic pain and depression with dizziness, visual disturbance and loss of balance being the most common reported effects (56). Patients in these studies report these side effects were mild and did not pose a major burden on treatment maintenance. Nearly a third of patients in our study reported having no adverse effects from oral Ketamine. Side effects reported (Table 5) were largely mild. Furthermore, these effects may not be solely attributed to ketamine as concurrent pharmacological intervention was being utilised (Table 6).
Conversely, poor tolerability with high rates of adverse reactions have also been reported. In a study investigating subcutaneous ketamine for cancer pain the number needed to harm (NNH) was just 6 (57). In comparison, the number needed to treat (NNT) was 25. However, rapid dose escalation (from 100 mg to 300 mg to 500 mg) may account for the high rate of adverse reactions encountered in this study, unlike the usual gradual increases in an outpatient chronic pain setting. Our study suggests that relatlively lower doses of Ketamine (mean < 200 mg) in a carefully monitored chronic pain specialist outpatient department may result in fewer adverse effects.
The growing body of evidence to support Ketamine's safety and tolerability is based on short time-limited term studies. Unfortunately, evidence to support its safety with chronic use is lacking (58). Case reports suggest severe ulcerative cystitis (59) and hepatotoxicity (60) may develop with chronic ketamine use. Animal models suggest ketamine can induce hyperphosphorylated tau in the cerebral cortex, a hallmark of Alzheimer’s disease (61). Further research is needed provide a more accurate understanding of the effects associated with chronic usage.
Ketamine is a controlled medication in most countries. Prevalence of illicit recreational use in the general population is thought to be 0.8% (62). In the clinical setting, data is lacking as to the extent of illicit usage and diversion of prescriptions, particularly when used to treat chronic pain (63). A subset of a case series assessing the use of repeated IV ketamine infusions for up to 126 weeks to treat depression made no reports of addiction, dependence or abuse (64). Similar findings were seen in a 48 week trial of intranasal ketamine for depression (65).
The opioid crisis in the United States and elsewhere is a stark warning on the dangers of drug overpresciption (66). Therefore we must exercise caution when prescribing oral Ketamine to treat chronic pain, and limit its use to those with severe intractable chronic pain who have explored all other suitable interventions.
Limitations and strengths
As this is a single-centre tertiary care study based in one country (Ireland), our results may not readily generalisable to other centres or countries (67). However, multicentre-controlled studies of Ketamine treatment have shown similar improvements between centres and countries (68). The retrospective nature of our interviews may be susceptible to recall bias. Being an open-label study and lacking a control group, we acknowledge the possibility that some patients may have experienced a placebo effect of pain reduction (69). Furthermore, patients continued to have various concurrent pharmacological and procedural interventions whilst using oral ketamine. We therefore accept that these may have contributed to the improvements seen.
Patients’ views of pain can recalibrate over time. This recalibration, known as ‘Response Shift’ (RS), suggests that if a subjective symptom such as pain is measured using an outcome measure without incorporating RS, any true change may not be captured (70). Until we have pain measurement tools incorporating RS with scientific reliability/validity, then the patients’ word remains the best outcome measure (71, 72).
All patients were included regardless of pain type, severity, sex, medications, procedures, comorbid diagnoses, and disability level. Rather than focusing on specific pain syndromes with a predefined level of disability, this study demonstrates the overall effectiveness of oral ketamine with improvements in pain, mood and Qol with an ecological validity that may be useful for a busy tertiary pain clinic where chronic pain of all types and severity is encountered. This study contributes to the evidence for Ketamine as a useful treatment in a tertiary pain clinic for all types and severity of chronic pain and associated disabilities.
Conclusion
This retrospective study found that chronic pain patients reported improvements in pain, mood and quality of life (QoL) with oral ketamine in a real world outpatient setting.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving humans were approved by St Vincent University Hospital Research Ethics Committee. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
SA: Writing – original draft. AN: Writing – original draft. DW: Writing – original draft. AM: Writing – original draft. PG: Writing – original draft. MF: Writing – original draft. MB: Writing – original draft. PM: Writing – original draft. HG: Writing – original draft. SN: Writing – original draft. MO: Writing – review & editing. LK: Writing – review & editing. EO: Writing – review & editing. RD: Writing – original draft. SM: Writing – original draft. PM: Writing – original draft. SB: Writing – original draft. ER: Writing – original draft. LG: Writing – original draft. DR: Writing – original draft, Writing – review & editing, Formal Analysis, Supervision. KL: Writing – original draft, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
The authors acknowledge and are grateful for the assistance of the patients and staff of the Pain Management Clinic at St Vincents University Hospital, Dublin 4, Ireland.
Conflict of interest
KL has received previous funding from Medtronic Ltd not related to this research.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. World Health Organization. International statistical classification of diseases and related health problems. 11th revision. (2021) 6 (Retrieved September 2018).
2. Tang NK, Crane C. Suicidality in chronic pain: a review of the prevalence, risk factors and psychological links. Psychol Med. (2006) 36(5):575–86. doi: 10.1017/S0033291705006859
3. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. (2006) 10(4):287–333. doi: 10.1016/j.ejpain.2005.06.009
4. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH. The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain. (2010) 11(11):1230–9. doi: 10.1016/j.jpain.2010.07.002
5. Dueñas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. (2016) 9:457–67. doi: 10.2147/JPR.S105892
6. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet. (2012) 380(9859):2163–96. doi: 10.1016/S0140-6736(12)61729-2
7. Smith D, Wilkie R, Uthman O, Jordan JL, McBeth J. Chronic pain and mortality: a systematic review. PLoS One. (2014) 9(6):e99048. doi: 10.1371/journal.pone.0099048
8. Lerman SF, Rudich Z, Brill S, Shalev H, Shahar G. Longitudinal associations between depression, anxiety, pain, and pain-related disability in chronic pain patients. Psychosom Med. (2015) 77(3):333–41. doi: 10.1097/PSY.0000000000000158
9. Goldenberg DL. The interface of pain and mood disturbances in the rheumatic diseases. Semin Arthritis Rheum. (2010) 40(1):15–31. doi: 10.1016/j.semarthrit.2008.11.005
10. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. (2003) 163(20):2433–45. doi: 10.1001/archinte.163.20.2433
11. Murphy F, Nasa A, Cullinane D, Raajakesary K, Gazzaz A, Sooknarine V, et al. Childhood trauma, the HPA axis and psychiatric illnesses: a targeted literature synthesis. Front Psychiatry. (2022) 13:748372. doi: 10.3389/fpsyt.2022.748372
12. Center for Substance Abuse T. SAMHSA/CSAT treatment improvement protocols. Managing chronic pain in adults with or in recovery from substance use disorders. Rockville (MD): Substance Abuse and Mental Health Services Administration (US) (2012).
13. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. (2013) 19(6):370–80. doi: 10.1111/cns.12099
14. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. (2011) 14(2):145–61. doi: 10.36076/ppj.2011/14/145
15. Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. (2014) 77(2):357–67. doi: 10.1111/bcp.12094
16. Sigtermans MJ, van Hilten JJ, Bauer MCR, Arbous SM, Marinus J, Sarton EY, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. (2009) 145(3):304–11. doi: 10.1016/j.pain.2009.06.023
17. Culp C, Kim HK, Abdi S. Ketamine use for cancer and chronic pain management. Front Pharmacol. (2021) 11:599721. doi: 10.3389/fphar.2020.599721
18. Domino EF. Taming the ketamine tiger. Anesthesiology. (2010) 113(3):678–84. doi: 10.1097/ALN.0b013e3181ed09a2
19. Wan LB, Levitch CF, Perez AM, Brallier JW, Iosifescu DV, Chang LC, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. (2015) 76(3):247–52. doi: 10.4088/JCP.13m08852
20. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharml Sci. (1982) 71:539–42. doi: 10.1002/jps.2600710516
21. Domino EF, Domino SE, Smith RE, Domino LE, Goulet JR, Domino KE. Ketamine kinetics in unmedicated and diazepam premedicated subjects. Clin Pharmacol Ther. (1984) 36:645–53. doi: 10.1038/clpt.1984.235
22. Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after IV, nasal and rectal administration in children. Br J Anaesth. (1996) 77:203–7. doi: 10.1093/bja/77.2.203
23. Mangnus TJP, Bharwani KD, Stronks DL, Dirckx M, Huygen FJPM. Ketamine therapy for chronic pain in The Netherlands: a nationwide survey. Scand J Pain. (2021) 22(1):97–105. doi: 10.1515/sjpain-2021-0079
24. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci. (1982) 71:539–42. doi: 10.1002/jps.2600710516
25. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of IM and oral ketamine. Br J Anaesth. (1981) 53:805–10. doi: 10.1093/bja/53.8.805
26. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. (1998) 88:82–8. doi: 10.1097/00000542-199801000-00015
27. Hartvig P, Valtysson J, Lindner KJ, Kristensen JD, Karlsten R, Gustafsson LL, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers. Clin Pharmacol Ther. (1995) 58:165–73. doi: 10.1016/0009-9236(95)90194-9
28. Bell RF, Kalso EA. Ketamine for pain management. Pain Rep. (2018) 3(5):e674. doi: 10.1097/PR9.0000000000000674
29. Irwin SA, Iglewicz A, Nelesen RA, Lo JY, Carr CH, Romero SD, Lloyd LS. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. (2013) 16:958–65. doi: 10.1089/jpm.2012.0617
30. Andrade C. Oral ketamine for depression, 2: practical considerations. J Clin Psychiatry. (2019) 80:19f12838. doi: 10.4088/JCP.19f12838
31. Jonkman K, van de Donk T, Dahan A. Ketamine for cancer pain: what is the evidence? Curr Opin Support Palliat Care. (2017) 11(2):88–92. doi: 10.1097/SPC.0000000000000262
32. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. (2001) 16(9):606–13. doi: 10.1046/j.1525-1497.2001.016009606.x
33. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singap. (1994) 23(2):129–38. PMID: 8080219.
34. Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. (2004) 5(2):133–7. doi: 10.1016/j.jpain.2003.12.005
35. Mason VL, Skevington SM, Osborn M. A measure for quality of life assessment in chronic pain: preliminary properties of the WHOQOL-pain. J Behav Med. (2009) 32(2):162–73. doi: 10.1007/s10865-008-9187-y
36. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole MR. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. (2001) 94(2):149–58. doi: 10.1016/S0304-3959(01)00349-9
37. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain. (2000) 88(3):287–94. doi: 10.1016/S0304-3959(00)00339-0
38. Marchetti F, Coutaux A, Bellanger A, Magneux C, Bourgeois P, Mion G. Efficacy and safety of oral ketamine for the relief of intractable chronic pain: a retrospective 5-year study of 51 patients. Eur J Pain. (2015) 19(7):984–93. doi: 10.1002/ejp.624
39. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care. (2004) 42(12):1194–201. doi: 10.1097/00005650-200412000-00006
40. Riggs LM, Gould TD. Ketamine and the future of rapid-acting antidepressants. Annu Rev Clin Psychol. (2021) 17:207–31. doi: 10.1146/annurev-clinpsy-072120-014126
41. Levins KJ, Drago T, Roman E, Martin A, King R, Murphy P, et al. Magnetic resonance spectroscopy across chronic pain disorders: a systematic review protocol synthesising anatomical and metabolite findings in chronic pain patients. Syst Rev. (2019) 8(1):338. doi: 10.1186/s13643-019-1256-5
42. Roddy D, O'Keane V. Cornu ammonis changes are at the core of hippocampal pathology in depression. Chronic Stress (Thousand Oaks). (2019) 3:2470547019849376. doi: 10.1177/2470547019849376
43. Roddy D, Kelly JR, Farrell C, Doolin K, Roman E, Nasa A, et al. Amygdala substructure volumes in major depressive disorder. Neuroimage Clin. (2021) 31:102781. doi: 10.1016/j.nicl.2021.102781
44. Roddy DW, Kelly JR, Drago T, Raajakesary K, Haines M, O’Hanlon E. Neurobiochemistry alterations associated with major depression: a review of translational magnetic resonance spectroscopic studies. In: Kim Y-K, Amidfar M, editors. Translational research methods for major depressive disorder. New York, NY: Springer US (2022). p. 265–309.
45. Drago T, O’Regan PW, Welaratne I, Rooney S, O’Callaghan A, Malkit M, et al. A cmprehensive regional neurochemical theory in depression: a protocol for the systematic review and meta-analysis of 1H-MRS studies in major depressive disorder. Syst Rev. (2018) 7(1):158. doi: 10.1186/s13643-018-0830-6
46. Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being: a world health organization study in primary care. JAMA. (1998) 280(2):147–51. doi: 10.1001/jama.280.2.147
47. Jafarinia M, Afarideh M, Tafakhori A, Arbabi M, Ghajar A, Noorbala AA, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: a double-blind, randomized, controlled trial. J Affect Disord. (2016) 204:1–8. doi: 10.1016/j.jad.2016.05.076
48. Roman E, Weininger J, Lim B, Barry D, Tierney P, O’Hanlon E, et al. Untangling the dorsal diencephalic conduction system: a review of structure and function of the stria medullaris, habenula and fasciculus retrofexus. Brain Struct Funct. (2020) 225:1437–58. doi: 10.1007/s00429-020-02069-8
50. Gardon O, Faget L, Chu Sin Chung P, Matifas A, Massotte D, Kiefer BL. Expression of mu opioid receptor in dorsal diencephalic conduction system: new insights for the medial habenula. Neuroscience. (2014) 277:595–609. doi: 10.1016/j.neuroscience.2014.07.053
51. Loonen AJM. Role of neuroglia in the habenular connection hub of the dorsal diencephalic conduction system. Neuroglia. (2023) 4(1):34–51. doi: 10.3390/neuroglia4010004
52. Yang Y, Cui Y, Sang K, Dong Y, Ni Z, Ma S, et al. Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. Nature. (2018) 554(7692):317–22. doi: 10.1038/nature25509
53. Hadi MA, McHugh GA, Closs SJ. Impact of chronic pain on patients’ quality of life: a comparative mixed-methods study. J Patient Exp. (2019) 6(2):133–41. doi: 10.1177/2374373518786013
54. Patel AS, Farquharson R, Carroll D, Moore A, Phillips CJ, Taylor RS, et al. The impact and burden of chronic pain in the workplace: a qualitative systematic review. Pain Pract. (2012) 12(7):578–89. doi: 10.1111/j.1533-2500.2012.00547.x
55. Bekkering GE, Bala MM, Reid K, Kellen E, Harker J, Riemsma R, et al. Epidemiology of chronic pain and its treatment in The Netherlands. Neth J Med. (2011) 69(3):141–53. PMID: 21444943.
56. Schoevers RA, Chaves TV, Balukova SM, aan het Rot M, Kortekaas R. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry. (2016) 208:108–13. doi: 10.1192/bjp.bp.115.165498
57. Hardy J, Quinn S, Fazekas B, Plummer J, Eckermann S, Agar M, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. (2012) 30(29):3611–7. doi: 10.1200/JCO.2012.42.1081
58. Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. (2018) 5(1):65–78. doi: 10.1016/S2215-0366(17)30272-9
59. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. (2007) 69(5):810–2. doi: 10.1016/j.urology.2007.01.038
60. Lo RS, Krishnamoorthy R, Freeman JG, Austin AS. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singapore Med J. (2011) 52(3):e52–5. PMID: 21451916.
61. Wu ZG, Chen F, Wu H, Chen JX, Wei QT, Fu YQ, et al. Urinary metabonomics of rats with ketamine-induced cystitis using GC-MS spectroscopy. Int J Clin Exp Pathol. (2018) 11(2):558–67. PMID: 31938141; PMCID: PMC6958055.31938141
62. Office for National Statistics (ONS). Drug Misuse in England and Wales: year ending March 2020. (2020).
63. Sassano-Higgins S, Baron D, Juarez G, Esmaili N, Gold M. A review of ketamine abuse and diversion. Depress Anxiety. (2016) 33(8):718–27. doi: 10.1002/da.22536
64. Wilkinson ST, Katz RB, Toprak M, Webler R, Ostrof RB, Sanacora G. Acute and longer-term outcomes using ketamine as a clinical treatment at the Yale Psychiatric Hospital. J Clin Psychiatry. (2018) 79:17m11731. doi: 10.4088/JCP.17m11731
65. Wajs E, Aluisio L, Holder R, Daly EJ, Lane R, Lim P, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (SUSTAIN-2). J Clin Psychiatry. (2020) 81:19m12891. doi: 10.4088/JCP.19m12891
66. Ayoo K, Mikhaeil J, Huang A, Wąsowicz M. The opioid crisis in North America: facts and future lessons for Europe. Anaesthesiol Intensive Ther. (2020) 52(2):139–47. doi: 10.5114/ait.2020.94756
67. Bellomo R, Warrillow SJ, Reade MC. Why we should be wary of single-center trials. Crit Care Med. (2009) 37(12):3114–9. doi: 10.1097/CCM.0b013e3181bc7bd5
68. Corriger A, Voute M, Lambert C, Pereira B, Pickering G. Ketamine for refractory chronic pain: a 1-year follow-up study. Pain. (2022) 163(4):690–701. doi: 10.1097/j.pain.0000000000002403
69. Cepeda MS, Berlin JA, Gao CY, Wiegand F, Wada DR. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis. Pain Med. (2012) 13(4):575–95. doi: 10.1111/j.1526-4637.2012.01340.x
70. Mannion DE, Gilmartin JJ, McInerney V, Molony K, Basquille E, Waldron D. Exploring the innate human potential for positive adaptation in the face of impending mortality: is there a response shift in subjective quality of life over time in a group of patients with lung cancer receiving palliative treatment? Inter J Innov Res Med Sci. (2020) 5(05):160–9. doi: 10.23958/ijirms/vol05-i05/880
71. McInerney DV. An intervention using quality of life and symptom information as a clinical tool in patients with advanced cancer. Inter J Innov Res Med Sci. (2019) 4(08):517–24. doi: 10.23958/ijirms/vol04-i08/740
Keywords: oral, ketamine, chronic, pain, treatment-resistant
Citation: Al Mukhaizeem S, Nasa A, Waldron D, McDaid A, Gorman PJ, Featherstone M, Barry M, Murphy P, Gallagher H, Nair S, O’Connor M, Kelly L, O'Hora E, Dolan R, Mac Colgain S, McGrath J, Blouin S, Roman E, Gaffney L, Roddy DW and Levins KJ (2023) Investigating the effectiveness of oral ketamine on pain, mood and quality of life in treatment resistant chronic pain. Front. Pain Res. 4:1268985. doi: 10.3389/fpain.2023.1268985
Received: 4 August 2023; Accepted: 2 November 2023;
Published: 23 November 2023.
Edited by:
Trine Andresen, Aalborg University, DenmarkReviewed by:
Daniel J. Meara, Christiana Care Health System, United StatesDianna E. Willis, Burke-Cornell Medical Research Institute, United States
© 2023 Al Mukhaizeem, Nasa, Waldron, McDaid, Gorman, Featherstone, Barry, Murphy, Gallagher, Nair, O'Connor, Kelly, O'Hora, Dolan, Mac Colgain, McGrath, Blouin, Roman, Gaffney, Roddy and Levins. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kirk John Levins kirklevins@aim.com